The Association between Schizophrenia Clinical Severity and Obesity Risk: A Literature Review
DOI:
https://doi.org/10.47611/jsrhs.v10i4.2063Keywords:
Schizophrenia, Obesity, Antipsychotics, PANSSAbstract
Obesity is a highly prevalent illness in schizophrenia patients. This review evaluates recent literature on the relationship between obesity risk and schizophrenia psychopathology. Ten studies were gathered using online resources like Google Scholar, PubMed, and the Brown University Library. Nine of the ten studies analyzed the relationship between obesity and schizophrenia severity with the factor of antipsychotics, while the last study excluded antipsychotic influence. While the nine studies with antipsychotic treatment indicate an association between improvement in overall symptom severity and weight gain, five studies specify negative symptoms to be more indicative of weight gain than positive symptoms, and two studies state the opposite. The last (tenth) study implies the existence of a relationship between weight and clinical severity independent from antipsychotic use. More research needs to be done on the connection between obesity and schizophrenia severity prior to antipsychotic treatment.
Downloads
References or Bibliography
Aguilar, M. C., Gurpegui, M., Diaz, F. J., & de Leon, J. (2005). Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions. The British Journal of Psychiatry: The Journal of Mental Science, 186, 215–221. https://doi.org/10.1192/bjp.186.3.215
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. The American Journal of Psychiatry, 156(11), 1686–1696. https://doi.org/10.1176/ajp.156.11.1686
Alonso-Alonso, M., Woods, S. C., Pelchat, M., Grigson, P. S., Stice, E., Farooqi, S., Khoo, C. S., Mattes, R. D., & Beauchamp, G. K. (2015). Food reward system: Current perspectives and future research needs. Nutrition Reviews, 73(5), 296–307. https://doi.org/10.1093/nutrit/nuv002
Annamalai, A., Kosir, U., & Tek, C. (2017). Prevalence of obesity and diabetes in patients with schizophrenia. World Journal of Diabetes, 8(8), 390–396. https://doi.org/10.4239/wjd.v8.i8.390
Aschbacher, K., Adam, E. K., Crofford, L. J., Kemeny, M. E., Demitrack, M. A., & Ben-Zvi, A. (2012). Linking disease symptoms and subtypes with personalized systems-based phenotypes: A proof of concept study. Brain, Behavior, and Immunity, 26(7), 1047–1056. https://doi.org/10.1016/j.bbi.2012.06.002
Aschbacher, K., O’Donovan, A., Wolkowitz, O. M., Dhabhar, F. S., Su, Y., & Epel, E. (2013). Good Stress, Bad Stress and Oxidative Stress: Insights from Anticipatory Cortisol Reactivity. Psychoneuroendocrinology, 38(9), 1698–1708. https://doi.org/10.1016/j.psyneuen.2013.02.004
Bak, M., Fransen, A., Janssen, J., Os, J. van, & Drukker, M. (2014). Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLOS ONE, 9(4), e94112. https://doi.org/10.1371/journal.pone.0094112
Berry, D. C., Stenesen, D., Zeve, D., & Graff, J. M. (2013). The developmental origins of adipose tissue. Development (Cambridge, England), 140(19), 3939–3949. https://doi.org/10.1242/dev.080549
Boden, G. (2008). Obesity and Free Fatty Acids (FFA). Endocrinology and Metabolism Clinics of North America, 37(3), 635–ix. https://doi.org/10.1016/j.ecl.2008.06.007
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa021423
Cameron, I. M., Hamilton, R. J., Fernie, G., & MacGillivray, S. A. (2017). Obesity in individuals with schizophrenia: A case controlled study in Scotland. BJPsych Open, 3(5), 254–256. https://doi.org/10.1192/bjpo.bp.116.003640
Catapano, L., & Castle, D. (2004). Obesity in Schizophrenia: What can be Done About it? Australasian Psychiatry, 12(1), 23–25. https://doi.org/10.1046/j.1039-8562.2003.02054.x
Chokhawala, K., & Stevens, L. (2021). Antipsychotic Medications. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK519503/
Coodin, S. (2001). Body Mass Index in Persons with Schizophrenia. The Canadian Journal of Psychiatry, 46(6), 549–555. https://doi.org/10.1177/070674370104600610
Davis, J., Juarez, D., & Hodges, K. (2013). Relationship of Ethnicity and Body Mass Index with the Development of Hypertension and Hyperlipidemia. Ethnicity & Disease, 23(1), 65–70.
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. A. (2017). Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatric Disease and Treatment, 13, 2231–2241. https://doi.org/10.2147/NDT.S113099
Després, J.-P. (2006). Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk. European Heart Journal Supplements, 8(suppl_B), B4–B12. https://doi.org/10.1093/eurheartj/sul002
Dipasquale, S., Pariante, C. M., Dazzan, P., Aguglia, E., McGuire, P., & Mondelli, V. (2013). The dietary pattern of patients with schizophrenia: A systematic review. Journal of Psychiatric Research, 47(2), 197–207. https://doi.org/10.1016/j.jpsychires.2012.10.005
Duseja, A., & Chalasani, N. (2013). Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatology International, 7(2), 755–764. https://doi.org/10.1007/s12072-013-9480-x
Felson, D. T., Anderson, J. J., Naimark, A., Walker, A. M., & Meenan, R. F. (1988). Obesity and knee osteoarthritis. The Framingham Study. Annals of Internal Medicine, 109(1), 18–24. https://doi.org/10.7326/0003-4819-109-1-18
Fried, S. K., & Kral, J. G. (1987). Adipose Tissue of Morbidly Obese Patients: Clinical Implications of Distribution, Morphology, and Metabolism. Gastroenterology Clinics, 16(2), 207–213. https://doi.org/10.1016/S0889-8553(21)00286-7
Gonçalves, P., Araújo, J. R., & Martel, F. (2015). Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. European Neuropsychopharmacology, 25(1), 1–16. https://doi.org/10.1016/j.euroneuro.2014.11.008
Haddad, P. M., & Correll, C. U. (2018). The acute efficacy of antipsychotics in schizophrenia: A review of recent meta-analyses. Therapeutic Advances in Psychopharmacology, 8(11), 303–318. https://doi.org/10.1177/2045125318781475
Hasan, A. A.-H. (2019). The correlation between the quality of life and clinical variables among outpatients with schizophrenia. Psychiatry Research, 271, 39–45. https://doi.org/10.1016/j.psychres.2018.09.062
Hemmrich, K., Kappel, B. A., Paul, N. E., Goy, D., Luckhaus, C., Pallua, N., & Fehsel, K. (2011). Antipsychotic Drugs Increase Adipose Stem Cell Differentiation-Implications for Treatment With Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 31(5), 663–665. https://doi.org/10.1097/JCP.0b013e31822bf0a5
Hermes, E., Nasrallah, H., Davis, V., Meyer, J., McEvoy, J., Goff, D., Davis, S., Stroup, T. S., Swartz, M., Lieberman, J., & Rosenheck, R. (2011). The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research, 128(1), 166–170. https://doi.org/10.1016/j.schres.2011.01.022
Ho, P. A., Dahle, D. N., & Noordsy, D. L. (2018). Why Do People With Schizophrenia Exercise? A Mixed Methods Analysis Among Community Dwelling Regular Exercisers. Frontiers in Psychiatry, 9. https://doi.org/10.3389/fpsyt.2018.00596
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394(10202), 939–951. https://doi.org/10.1016/S0140-6736(19)31135-3
Hui, L., Ye, M., Tang, W., Chen, D.-C., Tan, Y.-L., Zhang, F., Liu, J., Liu, L., Chen, Y., Yang, F.-D., & Zhang, X. Y. (2015). Obesity correlates with fewer symptoms in schizophrenia treated with long-term clozapine: Gender difference. Psychiatry Research, 225(3), 741–742. https://doi.org/10.1016/j.psychres.2014.12.035
Iacono, W. G., & Beiser, M. (1992). Are males more likely than females to develop schizophrenia? The American Journal of Psychiatry, 149(8), 1070–1074. https://doi.org/10.1176/ajp.149.8.1070
Kapur, S., Agid, O., Mizrahi, R., & Li, M. (2006). How antipsychotics work—From receptors to reality. NeuroRx, 3(1), 10–21. https://doi.org/10.1016/j.nurx.2005.12.003
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261
Kirschner, M., Hager, O. M., Bischof, M., Hartmann-Riemer, M. N., Kluge, A., Seifritz, E., Tobler, P. N., & Kaiser, S. (2016). Deficits in context-dependent adaptive coding of reward in schizophrenia. Npj Schizophrenia, 2(1), 1–8. https://doi.org/10.1038/npjschz.2016.20
Klop, B., Elte, J. W. F., & Castro Cabezas, M. (2013). Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients, 5(4), 1218–1240. https://doi.org/10.3390/nu5041218
Kolotkin, R. L., Meter, K., & Williams, G. R. (2001). Quality of life and obesity. Obesity Reviews, 2(4), 219–229. https://doi.org/10.1046/j.1467-789X.2001.00040.x
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., Nielsen, J., Holst, J. J., Ekstrøm, C. T., Correll, C. U., Vilsbøll, T., & Fink-Jensen, A. (2017). Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 74(7), 719–728. https://doi.org/10.1001/jamapsychiatry.2017.1220
Li, Q., Chen, D., Liu, T., Walss-Bass, C., de Quevedo, J. L., Soares, J. C., Zhao, J., & Zhang, X. Y. (2016). Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia. Journal of Clinical Psychopharmacology, 36(6), 643–648. https://doi.org/10.1097/JCP.0000000000000594
Li, Q., Du, X., Zhang, Y., Yin, G., Zhang, G., Walss-Bass, C., Quevedo, J., Soares, J. C., Xia, H., Li, X., Zheng, Y., Ning, Y., & Zhang, X. Y. (2017). The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia. Psychiatry Research, 251, 131–136. https://doi.org/10.1016/j.psychres.2016.12.041
Lin, S.-H., Tseng, H.-H., Tsai, H. C., Chi, M. H., Lee, I. H., Chen, P. S., Chen, K. C., & Yang, Y. K. (2021). Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment. Clinical Psychopharmacology and Neuroscience, 19(1), 155–159. https://doi.org/10.9758/cpn.2021.19.1.155
Łopuszańska, U., & Makara-Studzińska, M. (2017). Relationship between antipsychotic medication, obesity and cognitive functions. Current Problems of Psychiatry, 18(4), 272–278. https://doi.org/10.1515/cpp-2017-0020
Meltzer, H. Y., Perry, E., & Jayathilake, K. (2003). Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research, 59(1), 19–27. https://doi.org/10.1016/S0920-9964(01)00326-7
Mezquida, G., Savulich, G., Garcia-Rizo, C., Garcia-Portilla, M. P., Toll, A., Garcia-Alvarez, L., Bobes, J., Mané, A., Bernardo, M., & Fernandez-Egea, E. (2018). Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizophrenia Research, 192, 69–74. https://doi.org/10.1016/j.schres.2017.04.002
Moore, T. A., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Essock, S. M., Finnerty, M., Marder, S. R., Miller, D. D., McEvoy, J. P., Robinson, D. G., Schooler, N. R., Shon, S. P., Stroup, T. S., & Miller, A. L. (2007). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry, 68(11), 1751–1762. https://doi.org/10.4088/jcp.v68n1115
Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. Pharmacy and Therapeutics, 39(9), 638–645.
Pérez-Iglesias, R., Martínez-García, O., Pardo-Garcia, G., Amado, J. A., Garcia-Unzueta, M. T., Tabares-Seisdedos, R., & Crespo-Facorro, B. (2014). Course of weight gain and metabolic abnormalities in first treated episode of psychosis: The first year is a critical period for development of cardiovascular risk factors. International Journal of Neuropsychopharmacology, 17(1), 41–51. https://doi.org/10.1017/S1461145713001053
Tian, Y., Liu, D., Wang, D., Wang, J., Xu, H., Dai, Q., Andriescue, E. C., Wu, H. E., Xiu, M., Chen, D., Wang, L., Chen, Y., Yang, R., Wu, A., Wei, C. W., & Zhang, X. (2020). Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. Schizophrenia Research, 215, 270–276. https://doi.org/10.1016/j.schres.2019.10.017
Tian, Y., Wang, D., Wei, G., Wang, J., Zhou, H., Xu, H., Dai, Q., Xiu, M., Chen, D., Wang, L., & Zhang, X. Y. (2021). Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls. Psychopharmacology, 238(3), 745–753. https://doi.org/10.1007/s00213-020-05727-1
WHO Expert Consultation. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England), 363(9403), 157–163. https://doi.org/10.1016/S0140-6736(03)15268-3
Published
How to Cite
Issue
Section
Copyright (c) 2021 Isabel Li; Jack Hester
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
